Clinical Trial Update: Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100 [Phase 1]

View source ↗

Summary

A Phase 1 study sponsored by BioVersys AG evaluated rifabutin lung penetration after multiple intravenous administrations of BV100. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections

Drugs mentioned

• BV100
• RIFABUTIN (Rifabutin)

Snippet

Sponsor: BioVersys AG | Conditions: Bacterial Infections | Phase 1 | Status: COMPLETED